Daily Cardiology Research Analysis
Three high-impact cardiology studies stood out: two individual-patient-data meta-analyses in European Heart Journal reshape coronary revascularization choices (TiNOS vs DES in ACS; paclitaxel-coated balloons vs DES in small-vessel CAD), and a mechanistic study linking atrial fibrillation to impaired brain glymphatic function that improves after ablation. Together they inform safer stent/device selection, validate a stentless strategy in small vessels, and reveal a novel AF–cognition pathway.
Summary
Three high-impact cardiology studies stood out: two individual-patient-data meta-analyses in European Heart Journal reshape coronary revascularization choices (TiNOS vs DES in ACS; paclitaxel-coated balloons vs DES in small-vessel CAD), and a mechanistic study linking atrial fibrillation to impaired brain glymphatic function that improves after ablation. Together they inform safer stent/device selection, validate a stentless strategy in small vessels, and reveal a novel AF–cognition pathway.
Research Themes
- Device selection and long-term safety in ACS PCI (TiNOS vs DES)
- Stentless revascularization strategy for small-vessel CAD (PCB vs DES)
- AF-related cognitive decline mediated by impaired brain glymphatic function and improvement post-ablation
Selected Articles
1. Atrial fibrillation catheter ablation, brain glymphatic function, and cognitive performance.
In AF patients, the DTI-ALPS index of glymphatic function was reduced vs controls, especially in nonparoxysmal AF, and correlated with worse performance on multiple cognitive tests. Mediation analyses suggested glymphatic dysfunction mediates AF-related cognitive decline, and the ALPS index improved after catheter ablation.
Impact: This study uncovers a mechanistic link between AF and cognitive impairment via impaired brain glymphatic function and shows reversibility after ablation, opening a new cardio-neuro axis for intervention.
Clinical Implications: Supports considering cognitive monitoring in AF and provides a mechanistic rationale for rhythm control (ablation) to mitigate neurocognitive decline, especially in persistent AF.
Key Findings
- AF patients had lower DTI-ALPS glymphatic index than healthy controls (P=.016), with nonparoxysmal AF lowest.
- Lower ALPS index correlated with worse executive function and processing speed (Trail Making, Digit Symbol, Digit Span, Stroop; all P<.05).
- Mediation analysis indicated glymphatic activity mediates the AF–cognition association; ALPS improved post-ablation (P=.015) in 50 patients.
Methodological Strengths
- Prospective before-and-after imaging with DTI-ALPS and comprehensive neuropsychological testing.
- Mediation analysis linking physiology (glymphatic function) to clinical cognition.
Limitations
- Non-randomized case-control and before–after design; potential confounding remains.
- Short-term post-ablation imaging; long-term cognitive outcomes were not assessed.
Future Directions: Randomized trials to test whether rhythm control improves long-term cognitive outcomes and to define which AF phenotypes benefit most mechanistically.
BACKGROUND AND AIMS: It remains unknown whether the brain glymphatic system, which is driven by the heartbeat-driven pulsation of arteries and is responsible for cerebral waste clearance, is impaired in atrial fibrillation (AF) and mediates cognitive dysfunction related to AF. The aim of this study was to assess brain glymphatic alterations in AF, their role in cognitive function, and whether catheter ablation can improve glymphatic activity. METHODS: In this case-control and prospective before-and-after study, patients with AF and healthy controls (HCs) were enrolled. Participants underwent brain magnetic resonance imaging and a comprehensive neuropsychological battery. Glymphatic activity was quantified by diffusion tensor image analysis along the perivascular space (DTI-ALPS) index. Magnetic resonance imaging was repeated after surgery in patients who underwent ablation. RESULTS: Overall, 87 patients with AF and 44 HCs were enrolled. Compared with HCs, patients with AF had a lower ALPS index (P = .016). Nonparoxysmal AF patients showed lower ALPS index than both HCs (P = .002) and paroxysmal AF patients (P = .044). A lower ALPS index was associated with worse scores of Trail Making Test, Digit Symbol Substitution Test, Digit Span Test, and Stroop Colour and Word Test (all P < .05). Mediation analyses revealed that glymphatic activity was a mediator between AF and cognitive decline. Among the 50 patients who underwent ablation therapy, DTI-ALPS index was improved after surgery (P = .015). CONCLUSIONS: Brain glymphatic function measured by DTI-ALPS index was impaired in patients with AF, mediates the association between AF and cognitive decline, and was improved after ablation therapy.
2. Titanium-nitride-oxide-coated vs. drug-eluting stents in acute coronary syndromes: an individual patient data meta-analysis.
Across three ACS RCTs with IPD (n=2743), TiNOS stents achieved similar 5-year MACE and TLR to DES but significantly lowered cardiac death, MI, and stent thrombosis. These safety advantages may influence device selection in ACS.
Impact: Demonstrates long-term safety gains with a non–drug-eluting coating strategy without efficacy loss, challenging DES hegemony in ACS and informing guideline debates.
Clinical Implications: TiNOS may be a preferred option in ACS patients at high thrombosis risk or where minimizing stent thrombosis and MI is paramount, with comparable revascularization efficacy.
Key Findings
- No significant difference in 5-year MACE between TiNOS and DES (12.6% vs 16.2%; HR 0.82; P=0.051).
- Similar ischaemia-driven TLR (8.0% vs 8.1%; HR 1.05; P=0.733).
- Significantly lower cardiac death (HR 0.46), MI (HR 0.56), and stent thrombosis (HR 0.30) with TiNOS.
Methodological Strengths
- Individual patient data meta-analysis of randomized trials with prespecified endpoints.
- Robust mixed-effects Cox modeling with stratified hazards over ~5-year follow-up.
Limitations
- Primary MACE difference was borderline (P=0.051); efficacy (TLR) was similar.
- Only three RCTs; potential variation in comparator DES generations and practice patterns.
Future Directions: Head-to-head contemporary trials and cost-effectiveness analyses to define subgroups most likely to benefit from TiNOS in ACS.
BACKGROUND AND AIMS: In acute coronary syndromes (ACS), vascular healing at the site of implantation of drug-eluting stents (DES) can be delayed. Titanium-nitride-oxide-coated stents (TiNOS) demonstrate faster strut coverage without the excessive intimal hyperplasia observed with bare metal stents. The 5-year outcomes of patients presenting with ACS, randomized to receive either TiNOS or DES, were compared. METHODS: A systematic review and individual participant data meta-analysis of trials comparing TiNOS with DES for the treatment of ACS was conducted (PROSPERO: CRD42024514342). The primary endpoint was major adverse cardiac events (MACE) at 5 years, a composite of cardiac death (CD), myocardial infarction (MI), and ischaemia-driven target lesion revascularization (TLR). Pre-specified secondary endpoints included CD, MI, TLR, and stent thrombosis. Data were pooled using a mixed-effects Cox regression model with random slope and stratified baseline hazards. RESULTS: Patient-level data (n = 2743) were obtained from three randomized controlled trials (TiNOS: n = 1620 vs. DES: n = 1123). After a median follow-up of 4.93 years, there was no significant difference in the primary endpoint between TiNOS and DES (12.6% vs. 16.2%; hazard ratio [HR] .82, 95% confidence interval [CI] .67-1.00, P = .051), mainly due to a similar rate of TLR (8.0% vs. 8.1%; HR 1.05, 95% CI .80-1.38, P = .733). However, TiNOS was associated with significantly lower rates of CD (1.5% vs. 3.7%; HR .46, 95% CI .26-.81, P = .007), MI (5.2% vs. 9.6%; HR .56, 95% CI .42-.75, P < .001), and stent thrombosis (1.1% vs. 3.8%; HR .30, 95% CI .17-.53, P < .001). CONCLUSIONS: In ACS patients, TiNOS was associated with similar rates of MACE and TLR as compared with DES but significantly lower rates of CD, MI, and stent thrombosis.
3. Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study.
Across three trials (n=1154), PCB angioplasty reduced 3-year MACE vs DES in small-vessel CAD, driven by lower MI and target vessel revascularization, with no significant difference in TLF and similar results vs second-generation DES.
Impact: Strengthens the evidence for a stentless strategy in small vessels, potentially reducing permanent metal implantation while maintaining efficacy.
Clinical Implications: PCB offers a viable alternative to DES in de novo small-vessel CAD with fewer MACE at 3 years and no TLF penalty, informing strategy where stent implantation may be suboptimal.
Key Findings
- PCB reduced 3-year MACE vs DES (HR 0.67; adjusted HR 0.75).
- No significant difference in 3-year TLF overall and vs second-generation DES.
- Sensitivity analysis including reconstructed data confirmed consistency for TLF (HR 0.87).
Methodological Strengths
- Investigator-initiated IPD meta-analysis with PROSPERO registration and 3-year follow-up.
- Multiple prespecified endpoints and landmark/two-stage analyses with sensitivity checks.
Limitations
- Total sample size remains modest; two-stage analysis did not reach statistical significance for MACE.
- Applies to paclitaxel-coated balloons; generalizability to newer sirolimus-coated platforms is unknown.
Future Directions: Large contemporary trials comparing PCB to modern DES and sirolimus-coated balloons with extended follow-up and cost-effectiveness analyses.
BACKGROUND AND AIMS: In randomized clinical trials of patients undergoing percutaneous coronary intervention (PCI) for de novo small-vessel coronary artery disease (SV-CAD), paclitaxel-coated balloon (PCB) angioplasty showed mid-term angiographic or clinical non-inferiority to drug-eluting stent (DES) implantation. Nevertheless, these trials have sample size limitations, and the relative safety and efficacy beyond the first year remain uncertain. METHODS: The ANDROMEDA study was a collaborative, investigator-initiated, individual patient data meta-analysis comparing 3 year clinical outcomes between PCB angioplasty and DES implantation for the treatment of de novo SV-CAD. Multiple electronic databases (PubMed, Scopus, ScienceDirect, and Web of Science) were searched from May 2010 to June 2024 to identify eligible trials. All the following eligibility criteria were required: (i) random allocations of treatments; (ii) patients with SV-CAD; (iii) treatment with PCB or DES; and (iv) clinical follow-up of at least 36 months. The primary and co-primary endpoints were major adverse cardiac events (MACE) and target lesion failure (TLF), respectively. The protocol was registered with PROSPERO (CRD42023479035). RESULTS: Individual patient data from three randomized trials, including a total of 1154 patients and 1360 lesions, were combined. At 3 years, PCB was associated with a lower risk of MACE compared with DES [hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.47-0.96], due to a lower risk of myocardial infarction and target vessel revascularization. This benefit persisted after multivariable adjustment (HR 0.75, 95% CI 0.58-0.96), but did not reach statistical significance in the two-stage analysis (HR 0.67, 95% CI 0.43-1.04). At the landmark analysis, the risk of MACE between groups was consistent over time. At 3 years, TLF was not significantly different between PCB and DES groups. Reconstructed time-to-event information from a fourth trial was included in a sensitivity analysis (1384 patients and 1590 lesions), showing consistent results in terms of TLF (HR 0.87, 95% CI 0.63-1.20). The comparison between PCB and second-generation DES did not reveal significant differences in 3 year TLF (HR 1.03, 95% CI 0.70-1.50). CONCLUSIONS: In patients undergoing PCI for de novo SV-CAD, PCB angioplasty is associated with a reduction in MACE and a non-significant difference in TLF at 3 year follow-up compared with DES implantation. The restriction of the comparator group to second-generation DES does not alter the main conclusions. Larger trials comparing contemporary devices at a more prolonged follow-up are warranted to confirm these findings.